April 25, 2026 (View All Issues)
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identified patient datasets from participating cancer centers, while maintaining patient security,...
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
Dietary Influence on Leukemia and Lymphoma Progression
In 2015, LH, a 66-year-old female, was diagnosed with chronic lymphocytic leukemia (CLL), Rai stage 0. Untreated, the woman’s lymphocyte count rose from 5,000/mm3 to 16,000/mm3 in 6 years (doubling time = 4.2 years). She was then advised to stop eating red meat (see the figure). Commercially...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
GLP-1 RAs May Reduce Mortality In Some Patients With Colorectal Cancer and Comorbid Obesity: Real-World Outcomes
Colon cancer is among the leading causes of cancer-related morbidity and mortality worldwide, with alarming increases in incidence and mortality among younger adults. Although the exact causes of these increases are unknown, lifestyle, including poor diets, sedentary habits, smoking, and alcohol...
Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center
International leader in blood cancer and stem cell research Ulrich Steidl, MD, PhD, has been named Director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Vice President of Cancer Medicine at Montefiore Einstein. He has acted as Interim Director of MECCC, which is a National...
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1
“Mandatory and uniform reporting of all [venous and arterial ...
Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1
The update to...
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-line setting, according to findings presented during the first European Society for Medical...
Cancer Researcher Awarded Sjöberg Prize For Describing Tumors’ Evolution
This year’s Sjöberg Prize of $1 million U.S. dollars was awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumors. Professor Charles Swanton, FRCP, BSc, PhD, at the Francis Crick Institute in London, described how tumors’ mutations arise and develop....
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
Long-Time ASCO Member Philip A. Salem, MD, Honored for Medical Excellence, Leadership, and Compassion
On January 29, 2026, Baylor St. Luke’s Medical Center and the Dan L Duncan Comprehensive Cancer Center formally dedicated the Philip A. Salem, MD Conference Center at the O’Quinn Medical Tower. On this occasion, both the governor of Texas and the mayor of the city of Houston made proclamations,...
